Purple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEO
- Purple Biotech (NASDAQ:PPBT) on Friday said that the CEO, Gil Efron, has been hospitalized following a mishap and will be on medical leave, which is expected to last several months while he undergoes rehabilitation to recover from his injuries.
- The board appoints Isaac Israel, a current board member and the former CEO, to serve as acting CEO during Gil Efron’s absence.
- The company’s business plan and clinical development programs continue as planned.